Therma Bright (TSXV: THRM) this morning provided a brief update to investors on the status of its clinical study. The study is currently looking to evaluate its COVID-19 rapid antigen saliva test for performance.
The clinical performance study being conducted on the test is reportedly still underway, with the study expected to be completed this month. The study is currently looking to utilize up to 300 participants to determine the tests effectiveness at detecting the virus.
Somewhat ironically, the performance testing of the rapid antigen saliva test has been delayed due to the current wave of the virus overwhelming the firms clinics and labs with PCR testing. The strong demand for testing services has slowed down the time between receiving lab-based tests and cross referencing the results with results from the saliva tests.
In commenting on the results seen to date, Rob Fia, CEO of Therma Bright stated, “Current results are very promising, as we look to be the first COVID-19 rapid antigen saliva test to receive FDA Emergency Use Authorization.”
Therma Bright last traded at $0.37 on the TSX Venture.
Information for this briefing was found via Sedar and Therma Bright Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
